Becton Dickinson and Company

Becton, Dickinson and Company has deployed its next-generation pharmacy automation robot, BD Vmax 160, at Fairview Health Services, marking the first U.S. health system to adopt the system. Fairview, which fills an average of 20,000 prescriptions per week across 25 outpatient pharmacies and mail-order services in Minnesota, is building on an existing collaboration with BD that includes the BD Parata Max 2 high-speed vial filling robot and the BD Incada Connected Care Platform. The Vmax 160 is designed for centralized fulfillment environments, featuring the BD EasyLoad system for overnight inventory replenishment with a reported three-second loading time per tote and 99.8% accuracy, automated labeling that supports requirements across all 50 states, cold-chain support for medications stored between 2°C and 8°C, and smart expiry detection that blocks expired products from being dispensed. Following the announcement, BDX stock gained 2.8% at yesterday's close, though shares have lost 5.8% year to date against the industry's 5% growth, with the S&P 500 up 11.1% over the same period. BDX currently has a market capitalization of $49 billion. Separately, BD said the STANCE trial of GalaFLEX LITE Scaffold surpassed 50% of its maximum planned enrollment with 274 patients treated across 33 U.S. sites, and it completed enrollment of 477 patients across 32 U.S. and European sites in the PREVENT trial evaluating Phasix Mesh for incisional hernia prevention.

Four industry sponsors have committed $100,000 to launch the Medicinal Hazard Data Standardization Consortium, a nonprofit global collaboration developing standardized Medicinal Hazard Data Sheets. The funding from Pharmacy Stars, BD, EQUASHIELD, and EuroBioConcept addresses the fragmented hazardous drug classification across NIOSH, USP <800>, ISOPP, and European directives, which leaves hospitals and pharmacies to independently assess toxicological risks. The consortium will maintain an open, consensus-governed framework to identify and communicate hazards across the drug lifecycle, with outputs free from commercial influence. The announcement coincides with the 84th FIP World Congress in Montréal, where a presentation on an internationally harmonized hazardous drug list will be given on September 1.

BD (Becton, Dickinson and Company) announced that its STANCE clinical trial evaluating GalaFLEX LITE™ Scaffold in breast revision surgery for capsular contracture has reached its first enrollment milestone, with 274 patients treated across 33 active U.S. sites, triggering the first planned interim analysis. This enrollment surpasses 50% of the trial's maximum planned enrollment, which is expected to range from 250 to 530 patients under the adaptive design. Capsular contracture, the most frequent complication of implant-based breast surgery, has an overall incidence of 10% to 20%, and recurrence risk may be as high as 54% with conventional techniques. The study aims to support an FDA Premarket Approval application for a breast indication for GalaFLEX LITE™ Scaffold, which is composed of poly-4-hydroxybutyrate (P4HB), a bioabsorbable polymer with over 10 years of clinical use in soft tissue support.

Becton Dickinson has completed patient enrollment in its PREVENT clinical trial for Phasix Mesh, a potential first-in-class option for preventing incisional hernias. The milestone follows recent updates including new quality leadership appointments, conference appearances, and a recall-related correction notice. The stock has returned 25.36% over the past 30 days and 30.05% over 90 days, while the one-year total shareholder return is 25.37% and the three-year total shareholder return shows a decline of 7.43%. A widely followed valuation narrative puts Becton Dickinson's fair value at about $189.58, slightly below the last close of $192, implying the stock is about 1% overvalued. The company is also planning to separate its Biosciences and Diagnostic Solutions business to become a pure-play medical technology leader with over 90% of revenue from consumables.

Surgical equipment and consumables stocks tracked by StockStory delivered a strong second quarter, with group revenues beating analysts' consensus estimates by 1.6%. STERIS reported revenues of $1.49 billion, up 7.3% year on year, in line with expectations but with the weakest performance against analyst estimates of the group. Solventum posted revenues of $2.21 billion, up 2.2% year on year, outperforming expectations by 2.5% and delivering the biggest analyst estimate beat among its peers. Zimmer Biomet reported revenues of $2.18 billion, up 4.8% year on year, exceeding expectations by 2%, while CONMED reported revenues of $343.5 million, flat year on year, beating expectations by 1.8%. BD reported revenues of $4.98 billion, up 5.4% year on year, topping expectations by 2%.

Four Dividend Kings—Becton, Dickinson and Company, Consolidated Edison, Emerson Electric, and Parker-Hannifin—reported quarterly earnings last week, with all four currently carrying a Zacks Rank #3 (Hold). Becton Dickinson beat fiscal third-quarter adjusted earnings estimates with $3.23 per share versus $3.14 expected, raised its fiscal 2026 adjusted EPS midpoint to $12.62-$12.72, and saw year-to-date free cash flow rise over 44% to $1.7 billion. Consolidated Edison posted second-quarter adjusted earnings of 83 cents per share, ahead of the 74-cent estimate, and reaffirmed its fiscal 2026 adjusted EPS guidance of $6.00-$6.20 while planning nearly $38 billion in capital expenditures from 2026 through 2030. Emerson Electric's fiscal third-quarter adjusted EPS rose over 12% to $1.71, beating estimates by 3 cents, and the company raised its fiscal 2026 outlook to approximately $19 billion in net sales and adjusted EPS of around $6.55. Parker-Hannifin's fiscal fourth-quarter adjusted earnings surged 20% to $9.27 per share, easily topping the $8.29 estimate, with orders soaring 19% year over year, and management guided fiscal 2027 adjusted EPS to $34.25-$35.25 excluding pending acquisitions.

BD reported fiscal third quarter 2026 revenue of $5 billion, up 4.4%, with adjusted EPS of $3.23, beating expectations and prompting the company to raise the midpoint of its full-year adjusted EPS guidance to a range of $12.62 to $12.72. CEO Tom Polen said more than 90% of the portfolio delivered high single-digit growth, driven by double-digit gains in biologic drug delivery, advanced patient monitoring, PureWick, and advanced tissue regeneration, while known headwinds in Alaris and China vaccines played out as expected. CFO Vitor Roque noted adjusted operating margin was 24.9%, down 130 basis points year over year due to about 110 basis points of tariff impact, and free cash flow rose 45% year-to-date to $1.7 billion. The company reiterated that fiscal 2027 revenue growth is expected to be low single digits, with a 200 basis point headwind from the end of Alaris remediation, and said it will provide formal guidance in November.

Becton, Dickinson and Company shares climbed 6.8% after reporting third-quarter fiscal 2026 results that beat expectations and announcing new GLP-1 delivery partnerships. Sales rose to US$4,983 million while net income fell to US$377 million, and the company modestly raised its full-year outlook for low single-digit plus GAAP revenue growth. BD highlighted strong momentum in biologic drug delivery and a new semaglutide pen collaboration with EMS in Brazil, underscoring the growing role of its Vystra Injection Pen platform in chronic disease treatment. The affirmed US$4.20 annual dividend and share price recovery suggest the market views the quarter as a mild positive, though the sharp drop in year-to-date net income and a large recent one-off loss keep the quality of earnings in focus.

The crisis of antimicrobial resistance, or superbugs, is driving investment into the AMR Diagnostics sector, which serves as the diagnostic and containment infrastructure for drug-resistant infections. By 2050, superbugs could claim more lives than cancer if adequate systems are not in place. Danaher Corporation, through its subsidiary Cepheid, leads in molecular diagnostic radar systems with the GeneXpert instrument, generating recurring revenue from test cartridges. Meanwhile, Becton, Dickinson and Company dominates the automated microbiology lab market with a consumables sales model that carries very high switching costs. Investment in this sector is thus seen as a defensive theme with predictable cash flows and strong demand from public health systems worldwide.

BD's Board of Directors has declared a quarterly dividend of $1.05 per common share. The dividend is payable on September 30, 2026, to shareholders of record as of September 9, 2026. The indicated annual dividend rate is $4.20 per share.

The global apheresis market is projected to grow from USD 3.02 billion in 2026 to USD 4.41 billion by 2031, at a compound annual growth rate of 7.9%. Disposables hold the largest product share, driven by recurring demand from blood collection and therapeutic procedures. Plasmapheresis leads by procedure, supported by rising demand for plasma-derived therapies and increasing plasma donations. North America maintained the largest regional market share in 2025, reflecting high disease prevalence and broad adoption of apheresis technologies. Key players include Terumo Corporation, Fresenius SE & Co. KGaA, Haemonetics Corporation, and Becton, Dickinson and Company.

BD announced that its CentroVena One Insertion System has been awarded an Innovative Technology contract by Vizient. The system integrates the guidewire, needle, syringe, and catheter into a single device, achieving 30% fewer procedural steps and reducing maximum procedure time by up to 50% compared to standard techniques. The contract was selected by hospital experts on Vizient's client-led councils and aims to make the technology more accessible to Vizient's network of healthcare providers.

The global IV equipment market is projected to grow from USD 17.82 billion in 2026 to USD 23.92 billion by 2031, at a compound annual growth rate of 6.1%, according to a new report added to ResearchAndMarkets.com. Growth is driven by rising chronic disease prevalence, increasing hospitalizations, and a shift toward home-based and outpatient care, with technological advancements such as needle-free connectors and smart infusion pumps boosting adoption. North America leads the market due to robust healthcare infrastructure and high adoption of medical technologies. Key players include Becton, Dickinson and Company, B. Braun SE, and Fresenius SE.

BD has been awarded an Innovative Technology contract from Vizient for its CentroVena One Insertion System, recognizing the device as a breakthrough innovation in central line insertion. The contract was granted after a review by Vizient's client-led councils, which found that the all-in-one system offers differentiated capabilities to enhance clinical care, improve patient and clinician safety, and streamline procedural workflows. CentroVena One is the first and only all-in-one central venous catheter insertion system, integrating the guidewire, needle, syringe, and catheter into a single system to reduce procedural complexity with 30% fewer steps and a 50% reduction in maximum procedure time compared to standard techniques. Vizient represents a diverse client base with more than $156 billion in annual purchasing volume, and the contract was awarded outside the competitive bid cycle through its Innovative Technology Program.

Three Dividend King stocks—AbbVie, Walmart, and Becton, Dickinson—are worth buying on recent price dips, according to a Motley Fool analysis. AbbVie shares are down 5% year to date amid healthcare sector weakness, but the drugmaker exceeded first-quarter expectations and its Skyrizi and Rinvoq franchises remain strong long-term growth drivers. Walmart’s stock dropped after its latest earnings on a cautious outlook, yet its Everyday Low Price model, expanding e-commerce and digital advertising, and 53-year streak of dividend increases support its long-term appeal. Becton, Dickinson has lagged the market amid slow growth, but over 90% of its revenue comes from recurring consumables, it is nearing a $1 billion target in GLP-1-related revenue, and it has raised its dividend for 54 consecutive years.

Deenova has started work on a new integrated automation and traceability system for drug management at the Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano. The project will be carried out by a temporary consortium led by Deenova, with Becton Dickinson Italia and GPI as participants. The architecture combines BD Rowa Vmax 160 for high-density storage in the central pharmacy, Ward Phasys by Riedl/GPI for controlled drug management in departmental areas, and Deenova's ALL-IN-1 Meds secure cabinets for decentralized storage and controlled access to drug packages in wards, all governed by Deenova's proprietary ORBIT middleware. The result is a resilient hospital pharmacy environment where central pharmacy automation, secure cabinets, ward-level drug control, and digital integration converge into a single coherent architecture for drug management and traceability.